Labiana Health

Labiana Health Accounts Payable

The Accounts Payable of Labiana Health (LAB.MC) as of Nov 19, 2026 is 11.37 M EUR. In the previous year, Accounts Payable was 8.77 M EUR — a change of 29.62% (higher).

Accounts Payable

11.37 MEUR

YoY

29.62%

Last updated:

Accounts Payable of Labiana Health is 2025 11.37 M EUR. Accounts Payable of Labiana Health was 2024 8.77 M EUR. It decreases by 29.62% higher compared to the previous year.

The Labiana Health Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2018
8.30 M EUR
Jan 1, 2019
7.83 M EUR
Jan 1, 2021
8.58 M EUR
Jan 1, 2022
11.33 M EUR
Jan 1, 2023
8.76 M EUR
Jan 1, 2024
8.77 M EUR
Jan 1, 2025
11.37 M EUR
The Labiana Health Accounts Payable history
YEARAccounts PayableYoY
11.37 MEUR+29.62%
8.77 MEUR+0.06%
8.76 MEUR-22.64%
11.33 MEUR+31.98%
8.58 MEUR+9.66%
7.83 MEUR-5.74%
8.30 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Labiana Health Stock analysis

What does Labiana Health do? Labiana Health SA generates revenue through the development, manufacturing, and marketing of animal and human medicines. The company focuses on drug research and development, including galenic and analytical development, as well as drug manufacturing, which encompasses formulation development and bacterial vaccine manufacturing. Regulatory services for pharmaceutical product registration in global markets also contribute to its income. Its subsidiaries operate in Ecuador, Mexico, Serbia, and Turkey, serving markets for both animal and human pharmaceutical products. The company's primary products include sterile and lyophilized dosage forms, which are manufactured for use in animal and human medicine. These products are sold to customers in the pharmaceutical industry, including distributors and healthcare providers in the regions where Labiana Health SA has a presence. The company’s R&D and manufacturing capabilities support the production of medicines that meet regulatory standards for global markets. Labiana Health SA’s business model relies on its subsidiaries in Ecuador, Mexico, Serbia, and Turkey to facilitate market access and distribution. The company’s revenue streams are derived from the sale of pharmaceutical products, regulatory services, and the development of new drug formulations. Its focus on sterile and lyophilized dosage forms positions it within the specialized pharmaceutical manufacturing sector, targeting both animal and human medicine segments. Labiana Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Labiana Health stock

Accounts Payable of Labiana Health is 11.37 M EUR in 2025.

Accounts Payable of Labiana Health changed from 8.77 M EUR to 11.37 M EUR, representing a 29.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Labiana Health since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Labiana Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Labiana Health

All Key Metrics — Labiana Health